Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma announced a conference call set for March 23, 2023, at 2 p.m. CET for discussing its financial results for the full year ending December 31, 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Interested parties can join via a webcast or telephone registration. Innate Pharma is focused on developing therapeutic antibodies aimed at enhancing cancer treatment, boasting a diverse pipeline and collaborations with major biopharmaceutical companies like Bristol-Myers Squibb and AstraZeneca. For more information, visit www.innate-pharma.com.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) confirms it has no financial exposure to Silicon Valley Bank, which was closed by California authorities. All cash and investments remain secure, unaffected by the bank's receivership. The company has an At-The-Market (ATM) program with SVB Securities, which operates independently and is not impacted by the closure. Innate Pharma maintains a robust liquidity position, ensuring ongoing operations will continue without disruption.
As of February 1, 2023, Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reports a total of 80,213,957 ordinary shares outstanding. Additionally, there are 6,514 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 80,971,797, while exercisable voting rights amount to 80,953,222. Innate Pharma specializes in developing therapeutic antibodies targeting cancer, with a focus on natural killer cell biology and tumor microenvironments, collaborating with major biopharmaceutical companies.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced participation in several upcoming investor conferences, focusing on oncology advancements. The conferences include:
- SVB Securities Global Biopharma Conference: February 14-16, 2023 (virtual)
- Citi's 2023 Virtual Oncology Leadership Summit: February 22, 2023 (virtual)
- H.C. Wainwright Cell Therapy Virtual Conference: February 28, 2023 (virtual)
Innate Pharma specializes in therapeutic antibodies aimed at enhancing cancer treatment. The company is recognized for its innovative approach, particularly regarding Natural Killer cell biology, and maintains significant partnerships with industry leaders.
Innate Pharma announced the expiration of the Hart-Scott-Rodino waiting period, making its licensing agreement with Sanofi effective. This collaboration involves Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKET® platform. The agreement includes a €25 million upfront payment and up to €1.35 billion in potential milestones, plus royalties on net sales. The ANKET® technology is designed to enhance cancer treatment by utilizing NK cells. Innate Pharma aims to leverage its innovative approach in oncology to address unmet medical needs.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) recently announced promising preclinical results published in Nature Biotechnology, demonstrating significant control of acute myeloid leukemia (AML) using a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. These findings indicate that CD123-NKCE can activate NK cells effectively against AML cells while minimizing toxicity. A Phase 1/2 clinical trial is currently underway, evaluating IPH6101/SAR’579 in patients with relapsed or refractory AML. Experts express optimism about its potential superiority over existing treatments.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has expanded its collaboration with Sanofi (NASDAQ: SNY) by granting an exclusive license for its B7H3 ANKETTM program. Sanofi will be accountable for all development and commercialization activities. Innate will receive an upfront payment of €25 million and up to €1.35 billion in potential milestones, along with royalties from net sales. This partnership continues the 2016 collaboration focused on NK cell engagers, enhancing Innate's cancer treatment portfolio and Sanofi's oncology strategy.
Innate Pharma, listed on Nasdaq under the ticker IPHA, recently presented encouraging results from the TELLOMAK Phase 2 trial of lacutamab for treating Sézary syndrome, demonstrating an objective response rate (ORR) of 21.6% in the intention to treat (ITT) population. In blood samples, the ORR was 37.8%, while skin samples showed 35.1% ORR. Lacutamab maintains a favorable safety profile with low incidence of severe treatment-related adverse events. The company aims to further explore lacutamab's efficacy in other T-cell lymphomas.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has provided an update on its outstanding shares as of December 1, 2022. The company reports a total of 80,812,069 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights is 80,969,909, while the exercisable voting rights are noted as 80,951,334. This disclosure aligns with French stock-market regulations and aims to keep the market informed about the company’s capital structure.
Innate Pharma announced three poster presentations at the ESMO Immuno-Oncology Annual Congress on December 8, 2022, in Geneva, Switzerland. The posters include Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, presented by AstraZeneca, and preclinical data supporting its Phase 2 development in non-small cell lung cancer. The IPH5301, a CD73-blocking antibody, will also be showcased along with the trial design.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
